Gossamer Bio, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2022. For the fourth quarter, the company reported net loss was USD 55.76 million compared to USD 56.28 million a year ago. Basic loss per share from continuing operations was USD 0.59 compared to USD 0.74 a year ago. Diluted loss per share from continuing operations was USD 0.59 compared to USD 0.74 a year ago.

For the full year, the company reported net loss was USD 229.38 million compared to USD 234 million a year ago. Basic loss per share from continuing operations was USD 2.71 compared to USD 3.13 a year ago. Diluted loss per share from continuing operations was USD 2.71 compared to USD 3.13 a year ago.